Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Kidney Neoplasms

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00091611

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: rituximab
Drug: fludarabine phosphate

First Posted Date: 2004-09-10

Last Posted Date: 2016-07-20

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 104

Registration Number: NCT00003248

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States

and more 31 locations

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-09-08

Last Posted Date: 2013-04-04

Lead Sponsor: Providence Cancer Center, Earle A. Chiles Research Institute

Target Recruit Count: 20

Registration Number: NCT00091143

Locations: 🇺🇸
Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-09-08

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 136

Registration Number: NCT00091104

Locations: 🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Rituximab
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide

First Posted Date: 2004-08-25

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 552

Registration Number: NCT00090051

Locations: 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸
Rush-Presbyterian St. Luke'S Medical Center, Chicago, Illinois, United States
🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

and more 103 locations

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2004-08-06

Last Posted Date: 2012-04-19

Lead Sponsor: University of Arkansas

Target Recruit Count: 10

Registration Number: NCT00089453

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Drug: mycophenolate mofetil
Drug: tacrolimus
Other: laboratory biomarker analysis
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation

First Posted Date: 2004-08-05

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT00089011

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 2 locations

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: Filgrastim
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine (Ara-C)
Drug: Fludarabine Phosphate
Drug: Idarubicin
Drug: Methylprednisolone
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-07-30

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00002833

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: fludarabine phosphate
Drug: octreotide acetate

First Posted Date: 2004-07-29

Last Posted Date: 2016-12-15

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 34

Registration Number: NCT00002779

Locations: 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
🇺🇸
CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States

and more 17 locations

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-07-12

Last Posted Date: 2013-08-02

Lead Sponsor: Bayer

Registration Number: NCT00086775

Locations: 🇺🇸
Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy